Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells

OBJECTIVES: Renal cell carcinoma (RCC) was the most common and lethal urological malignancy with the dismal outcome when distant metastasis. Melatonin was known as a potential oncostatic agent against several types of malignancy and sorafenib had been considered as an agent to treat RCC, but the syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chu-Che, Huang, Po-Yu, Hsieh, Yi-Hsien, Chen, Yong-Syuan, Tsai, Jen-Pi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020234/
https://www.ncbi.nlm.nih.gov/pubmed/35465276
http://dx.doi.org/10.4103/tcmj.tcmj_204_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020234/
https://www.ncbi.nlm.nih.gov/pubmed/35465276
http://dx.doi.org/10.4103/tcmj.tcmj_204_21

Ejemplares similares